STOCKS TELEGRAPH

Tag: NVAX stock

  • Should I Invest in Novavax Stock Right Now? Key Insights for 2025

    Should I Invest in Novavax Stock Right Now? Key Insights for 2025

    Novavax Inc. (NASDAQ: NVAX) has been a high-profile stock in the biotech sector, especially after its COVID-19 vaccine gained global attention. However, as the vaccine landscape evolves and new health threats emerge, investors are asking: Should I invest in Novavax stock right now?

    This article explores NVAX stock performance, financials, growth potential, risks, and market trends to help you make an informed investment decision.

    Recent NVAX Stock Trends & Price Movements


    Novavax Inc. (NASDAQ: NVAX) is currently trading at $7.87, with a previous close of $7.90 and an opening price of $7.87. The stock has experienced fluctuations within the day, reaching a high of $8.48 and a low of $7.87.

    With a market capitalization of $1.34 billion, Novavax remains a prominent player in the biotech industry despite facing financial challenges. The company has 160.84 million outstanding shares, with an impressive free float of 91.23%, indicating high liquidity in the market.

    Novavax’s earnings per share (EPS) (TTM) stands at -$1.23, reflecting its ongoing profitability struggles. Its price-to-earnings (P/E) ratio is -6.78, emphasizing that the stock is currently trading at a loss. The book value per share is -$5.80, while the cash flow per share is -$6.25, raising concerns about its long-term financial sustainability.

    Despite its challenges, trading volume has been strong, with 5.07 million shares exchanged in the latest session, demonstrating continued investor interest. As Novavax works to diversify its vaccine portfolio, investors will be watching closely to see if the stock can regain momentum.

    Novavax stock has experienced high volatility, largely influenced by its vaccine sales, regulatory approvals, and competition from major pharmaceutical companies like Pfizer (PFE) and Moderna (MRNA).

    Novavax’s Pipeline: Advancing Vaccine Innovation

    Novavax Inc. (NASDAQ: NVAX) is expanding its vaccine pipeline, leveraging its recombinant protein-based nanoparticle technology and proprietary Matrix-M™ adjuvant platform. The company is strategically investing in high-value assets targeting areas with unmet medical needs, strong scientific rationale, and substantial commercial opportunities. By adopting a disciplined and capital-efficient R&D approach, Novavax aims to develop early-stage and late-stage vaccine candidates while managing costs effectively.

    Key Vaccine Candidates in Development

    Respiratory Diseases

    • COVID-19 Vaccine – Novavax’s COVID-19 vaccine is already authorized for use in multiple regions, providing an alternative to mRNA-based vaccines.
    • COVID-19 + Seasonal Influenza Combination Vaccine (CIC) – Currently in Phase 3 trials, this vaccine aims to offer dual protection against COVID-19 and influenza in a single dose.
    • Influenza Vaccine (Older Adults) – A Phase 3 vaccine targeting seasonal influenza in older adults, aiming to enhance protection for a high-risk population.
    • Respiratory Syncytial Virus (RSV) Combinations – In preclinical development, this program explores RSV combinations targeting human metapneumovirus (hMPV) and other respiratory viruses.
    • H5N1 Avian Pandemic Influenza Vaccine – Another preclinical candidate, this vaccine is being developed for highly pathogenic avian influenza strains to mitigate future pandemic risks.

    Viral & Bacterial Infections

    • Shingles Vaccine (Varicella-Zoster Virus) – In preclinical trials, this vaccine aims to provide long-term immunity against shingles, a condition affecting older adults.
    • C. difficile Colitis Vaccine – Designed to combat Clostridioides difficile (C. diff) infections, this vaccine is currently in preclinical development, addressing a major cause of antibiotic-resistant infections.

    Partnered Vaccine Development Using Novavax’s Technology

    Novavax is also collaborating with partners to expand its vaccine portfolio beyond respiratory diseases:

    • Malaria Vaccine (R21/Matrix-M™ Adjuvant) – Developed using Novavax’s Matrix-M™ adjuvant, this malaria vaccine has been authorized for use, marking a breakthrough in parasitic disease prevention.
    • COVID-19 + Seasonal Influenza High-Dose Vaccine (TIV-HD & RIV3) – Two combination vaccines, currently in Phase 1/2 trials, explore the potential of integrating COVID-19 and flu protection using Fluzone High-Dose and Flublok technologies.

    Novavax’s focus on next-generation vaccines positions the company as a leader in infectious disease prevention. With multiple late-stage trials and authorized vaccines already in circulation, Novavax continues to strengthen its pipeline, expanding into new areas of unmet medical need.

    Factors Driving NVAX Stock Price

    1. COVID-19 Vaccine Demand: Novavax remains a player in the COVID-19 booster market, but its growth depends on continued demand.
    2. Pipeline Products: The company is expanding beyond COVID-19 vaccines, working on flu vaccines, RSV vaccines, and potential combination shots.
    3. Strategic Partnerships: Collaborations with global health organizations could boost funding and product distribution.
    4. Regulatory Approvals: Further FDA and EMA approvals could push NVAX stock upward.

    Novavax Financial Overview

    Revenue & Earnings

    In its latest earnings report for Q4 2024 (December 2024), Novavax (NVAX) posted an EPS of -$0.52, falling just $0.01 short of analyst expectations. Revenue for the quarter came in at $88.31 million, surpassing forecasts by $3.93 million, despite experiencing a steep 69.69% year-over-year decline. This significant drop in revenue reflects ongoing challenges, including declining demand for COVID-19 vaccines and broader industry headwinds. While Novavax managed to beat revenue estimates, the company remains under pressure to diversify its pipeline and stabilize its financial outlook in 2025.

    NVAX Recent Analyst Ratings: Mixed Sentiment but Strong Buy Ratings Persist

    Novavax (NVAX) has continued to attract attention from analysts, with multiple firms maintaining a “Buy” rating despite adjustments in price targets. Analysts remain cautiously optimistic about the company’s long-term potential, particularly in light of its pipeline developments and strategic initiatives.

    • December 10, 2024 – HC Wainwright & Co.’s Vernon Bernardino reiterated a “Buy” rating with a $19 price target, reflecting confidence in Novavax’s market position.
    • October 16, 2024 – Jefferies’ Roger Song maintained a “Buy” rating but lowered the price target from $31 to $25, signaling concerns about revenue performance.
    • October 10, 2024 – B. Riley Securities’ Mayank Mamtani reiterated a “Buy” rating, increasing the price target from $23 to $26, suggesting potential upside amid recent developments.
    • October 2, 2024 – Jefferies’ Roger Song maintained a “Buy” rating with a $31 price target, showing continued optimism in the company’s prospects.
    • August 2, 2024 – B. Riley Securities maintained a “Buy” rating but adjusted its price target from $29 to $25, reflecting shifts in market expectations.

    Growth Drivers: Why Novavax Stock Could Rise in 2025

    Expansion Beyond COVID-19 Vaccines

    Novavax is working on new-generation vaccines that could provide long-term revenue:

    • NanoFlu (influenza vaccine)
    • RSV Vaccine
    • COVID-Influenza Combo Vaccine (Phase 2 trials)

    Global Vaccine Market & Partnerships

    • Deals with WHO, CEPI, and Gavi enable Novavax to expand internationally.
    • Manufacturing partnerships with Serum Institute of India enhance production capabilities.
    • Government funding for pandemic preparedness keeps NVAX relevant in the biotech space.

    Potential Buyout & M&A Activity

    Given its strong vaccine technology, Novavax could be an acquisition target for a larger pharmaceutical company.

    Risks & Challenges Facing Novavax Stock

    Declining COVID-19 Vaccine Sales

    With the pandemic no longer an emergency, demand for COVID-19 vaccines has dropped. Revenue dependency on boosters poses risks.

    Intense Competition in the Vaccine Industry

    • Pfizer, Moderna, and Johnson & Johnson dominate the mRNA vaccine market.
    • Novavax must differentiate itself with superior efficacy and affordability.

    Financial Instability & High Debt Levels

    • Consistent net losses raise concerns.
    • Stock dilution risk: Novavax may issue more shares to raise capital, potentially lowering stock value.

    Regulatory Uncertainty

    • Any FDA rejections or delays in approvals could cause stock volatility.
    • Manufacturing challenges have previously caused supply chain disruptions.

    Investor Sentiment & Market Outlook

    Institutional Ownership

    Institutional investors hold a significant stake in Novavax, Inc. (NVAX), with approximately 60.95% of shares owned by financial institutions. Among the leading institutional investors, GTS Securities LLC holds 212,000 shares, valued at approximately $1.01 million, representing 0.15% of Novavax’s total shares. Another key investor, IMC-Chicago, LLC, owns 68,320 shares, with an estimated value of $326,580, accounting for 0.07% of the company’s outstanding shares.

    This level of institutional ownership reflects ongoing interest in NVAX stock, though investor sentiment remains mixed given the company’s financial performance and market position.

    Investor Sentiment Analysis for Novavax (NVAX)

    Investor sentiment surrounding Novavax Inc. (NVAX) has experienced notable fluctuations over the past six months, reflecting changing market perceptions and industry trends.

    • One-Week Sentiment: NVAX’s sentiment score currently stands at 36.79, based on 27 social media mentions, 1 news article, and no opinion pieces. This marks a significant jump of 25.33 points from 11.46 the previous week, indicating renewed optimism. Over the past week, the sentiment score has fluctuated between 6.63 and 37.08.
    • One-Month Sentiment: A similar upward trend is seen in the one-month sentiment score, which remains at 36.79, reflecting the same social media and news article mentions. This represents a 25.33-point increase from the previous month’s 11.46, with sentiment ranging from 6.63 to 37.08 during this period.
    • Six-Month Sentiment: Over the longer term, sentiment has seen a decline. The six-month sentiment score stands at 13.02, based on 853 social media posts, 74 news articles, and 16 opinion pieces. This reflects a 7.61-point decrease from 20.63 six months ago, with sentiment ranging between 9.54 and 20.91 during this timeframe.

    The short-term surge in investor sentiment suggests increasing optimism, likely driven by recent developments, earnings updates, or pipeline progress.

    The Verdict: Should You Invest in Novavax Stock Right Now?

    After analyzing Novavax, Inc. (NVAX) from multiple perspectives—including financial performance, institutional ownership, sentiment trends, and analyst ratings—it’s clear that the stock presents both opportunities and risks for investors.

    Bullish Case for NVAX

    Novavax continues to invest in vaccine development, leveraging its Matrix-M™ adjuvant technology and expanding its pipeline in respiratory and infectious diseases. The company’s COVID-19 vaccine remains a key asset, with ongoing clinical trials for a combination flu and COVID vaccine, positioning it for future growth in the immunization market. Analyst ratings remain mostly bullish, with firms like HC Wainwright, Jefferies, and B. Riley Securities maintaining Buy ratings despite price target adjustments.

    Bearish Case for NVAX

    On the downside, financial challenges persist. The company’s latest earnings report revealed a 69.69% YoY decline in revenue, indicating struggles in maintaining sales momentum. Institutional ownership, while moderate at 60.95%, shows limited confidence from major investment firms. Additionally, sentiment data highlights short-term optimism but long-term caution, with one-week and one-month sentiment scores surging, while the six-month score declined.

    Final Recommendation

    For risk-tolerant investors, Novavax could be an intriguing speculative play, especially if its pipeline advancements yield positive results. However, those seeking stable, long-term growth may prefer to wait for sustained revenue improvements, stronger institutional backing, and a clearer profitability path before investing. As with all biotech stocks, potential investors should closely monitor clinical trial updates, regulatory developments, and earnings reports to make an informed decision.

  • Investor Optimism As Novavax (NVAX) Reports Growth And Teams Up With Sanofi

    Investor Optimism As Novavax (NVAX) Reports Growth And Teams Up With Sanofi

    Novavax, Inc. (NASDAQ: NVAX) has experienced a significant surge in its stock performance, buoyed by the unveiling of its financial outcomes. In the latest market session, NVAX shares displayed an impressive escalation of 137.14%, attaining $10.60 as per the most recent evaluation. Furthermore, a notable strategic collaboration is also driving this ascent on the US stock indices.

    Financial Performance Highlights

    For the first quarter of 2024, Novavax (NVAX) disclosed a total revenue generation of $94 million, contrasting with $81 million from the preceding year. Meanwhile, the net loss of $148 million also exhibited an enhancement compared to the $294 million recorded in the prior year.

    Strategic Partnership With Sanofi

    Earlier today, Novavax also publicized its participation in a co-exclusive licensing pact with Sanofi. The synergistic alliance between Novavax and Sanofi will enhance their ability to advance their mission of developing and enhancing accessibility to life-saving vaccines. Novavax is also gearing up for the initiation of its Phase 3 CIC and standalone influenza initiative in the latter part of this year.

    This pact further validates Novavax’s technological framework and presents a substantial opportunity to foster value creation and bolster global public health. It fortifies Novavax’s financial standing and cash inflow, enabling a heightened focus on research and development as well as pipeline expansion to expedite growth and foster enduring value for stakeholders.

    Revenue Opportunities And Financial Implications

    This collaboration signifies a potential multi-billion dollar revenue prospect for Novavax. The cumulative value encompassing upfront payments in the near term, Sanofi’s equity infusion, and potential milestones linked with Nuvaxovid sales and Sanofi’s flu-COVID-19 amalgam vaccine development, stands at approximately $1.3 billion. Within ten days, Novavax will get a $500 million upfront payment.

    A nearly $70 million equity investment in Novavax common stock will also be given to the company today, securing a 4.9% minority share. Up to $350 million in milestones pertaining to Nuvaxovid activities are attainable by Novavax. In addition, Novavax stands to gain an extra $350 million in milestones related to Sanofi’s combined flu-COVID-19 vaccine.

  • Novavax Inc. (NVAX)’s Covid Vaccine Might Hit U.S. Market Soon But there are Many Concerns

    The outbreak of Covid-19 ushered the world into utter chaos, followed by continuous fear. Pharma giants rushed to make a viable vaccine for the virus that was not slowing down despite worldwide mobility restrictions and lockdowns. While developing a vaccine was a challenge in itself, a viable one even more so, and to top it off, commercial availability was another. Still, Moderna and Pfizer, along with BionNTech came out victorious with their Covid jabs in 2020, falling behind was Novavax Inc. (NVAX). While the two giants were winning authorizations for their vaccines, NVAX was still dealing with a formal submission. However, the company is soon to announce the all-important FDA authorization of its Nuvaxovid after the review ends in early June. But even if the company wins the authorization, there are many concerns that have investors and experts worried.

    NVAX Stock’s Losses

    Since hitting its pandemic high of $331.68 a share, NVAX has retraced over 80%. Down more than 67% year to date, the stock is currently valued at a price of $47.00 per share as of May 26. In this week alone, the stock lost nearly 19.5% as investors weigh in on its future. Much of this downfall comes from management’s delays in the filings and applications regarding the vaccine, while negative investor sentiment also played a role this year.

    While this severely beaten-down price of the Covid vaccine maker does bring a good entry point, there are many factors to analyze before making the decision. Even if the company achieved the much-awaited authorization for its vaccine, would it be much meaningful at all now that the market is highly saturated? Let’s have a look at what it is and what it might be!

    NVAX’s Covid-19 Vaccine

    The company’s covid-19 vaccine NVX-CoV2373 is known as Nuvaxovid. Unlike the mRNA vaccines dominantly present in the U.S., Nuvaxovid is a protein-based vaccine. So far, the vaccine has shown great potential with all of its three pivotal, large-scale studies proving its efficacy. Last year, two trials in adults in the U.S., Mexico, and the U.K. yielded vaccine efficacies of 89.7% and 90.4%, respectively. The third trial in adolescents resulted in a vaccine efficacy of 80%, which was announced earlier this year. This makes NVAX the third drug maker to reach the threshold of 90% VE in Covid-19 trials. This also signals green to the possibility of its vaccines becoming a standard for initial inoculations and booster shots.  

    Saturated Market

    An FDA advisory committee is set to review NVAX’s Emergency Use Authorization (EUA) on June 7, 2022. Even if it is approved, this will still be way behind its rivals and a huge number of dollars short. According to the company, management is confident that the vaccines will receive authorization due to their strong efficacy results.

    Following its anticipated approval, the Covid jab will enter the U.S. market when 76% of adults are already fully vaccinated and the market is shared by giants like Pfizer and Moderna. Luckily for NVAX, Johnson & Johnson’s vaccine use was brought down by the FDA recently. However, the over-saturated market situation does not leave the company’s vaccine with much space.

    New Variants

    Another downside to entering the market at this point is the fact that the FDA is considering redesigning Covid shots to target its mutations. All the existing vaccines target the spike protein of the original strain, while today many new variants like delta and omicron are roaming-free. With the emergence of these new variants, the existing Covid vaccines have become less effective. Although the company is conducting studies on its modified vaccine in omicron, it is still a long way.

    The Upside

    On the upside, there are people who prefer protein-based vaccines over the recently accepted mRNA ones. Protein-based vaccines are based on older and potentially more trusted technology than mRNA jabs. There is even a debate going on regarding the downsides of mRNA vaccines. Moreover, the possibility of NVAX’s vaccine being a booster dose and approved for ages 12-17 also exists. This would help the company tap into the huge unmet need for a Covid shot for children in the U.S. More importantly, the company is projecting a full-year sales forecast of $4 billion to $5 billion.

    Financial Overview

    For Q1 2022, NVAX reported revenue of $704 million, which shot up by over 57% YOY. This included $586 million in sales of the Covid vaccine. However, the sales still fell short of the consensus estimate of $845 million.

    As a commercial-stage company, NVAX posted its first profitability with earnings of $203 million or $2.56 per diluted share. Much better than the loss of $233 million ($2.56/share) a year ago, the earnings still were below the expected $2.69 per share.

    The company is said to have delivered just 42 million doses of the Covid vaccines in Q1 while it maintains its full-year expectations of $4-$5 billion in sales. Management said demand is expected to pick up in Q2, while it still has to receive an order from Gavi. The advance purchase agreement with Gavi calls for the company to deliver 350 million doses. The company’s doses commitments are as below:

    Source: Company Investor Presentation

    Future Possibility

    While the company might not be able to beat advanced rivals Pfizer and Moderna right now, there’s huge potential and a big possibility in the future. A tremendous lift to the company can come from the fact that it is working on a combined coronavirus-flu candidate. With its coronavirus and flu candidates each having completed phase 3 trials with primary endpoints, NVAX is most likely to get to market first in this. The phase 2 trial of the combined candidate is set to be launched by the end of this year, while Phase 1 reported positive results. Moderna, which is also developing a combined candidate, is still in the preclinical stage. On top of it, the company does have a cash stockpile of $1.6 billion, more than enough to fund all its clinical programs.

    According to experts, Covid-19 is here to stay and in the future people would most likely be getting annual coronavirus shots along with flu shots. Thus, people would most definitely choose one combined shot over two separate ones.

    Conclusion

    While headwinds to the company exist due to lagging behind its advanced rivals, NVAX still has much potential for growth due to a number of reasons. Even if the current market is saturated, its protein-based technology does give it a little edge and its potential vaccine authorization for children opens a huge opportunity. A huge plus to the company becoming a leader in the future comes from its combined flu and coronavirus candidate, which has shown much potential so far. Hence, maybe the stock might not be the best buy right now, the future holds great prospects.

  • Novavax Inc (NVAX) stock lost 7.04% in the after-market. Here’s why

    The stock of Novavax Inc (NVAX) followed a bearish pattern in the after-market after releasing its financial outlook for Q4 and FY21. In the after-market, NVAX lost 7.04% to $77.5. NVAX closed the regular trading session at $83.37, gaining 2.13% from the previous trading session. The market capitalization of NVAX is $6.30 billion with 75.61 million shares pending.

    NVAX fiscal 2021

    On 28 February 2022, Novavax Inc released the financial performance for its Q4 and FY21, which concluded on 31 December 2021. Some important points are

    • The revenue for NVAX reduced by 20.5% to $222.2 million in Q4 of FY21 compared to $279.6 million in the corresponding period of last year. The yearly revenue grew by 141% from $475.5 million in 2020 to $1.14 billion in 2021.
    • The total loss of the company was reported to be $846.2 million in Q4 of FY21 in contrast to $177.5 million in Q4 of FY20. This marks a growth of 376.6% in the loss. The yearly loss was also up by 316.9% to $1.7 billion in 2021 versus $418.2 million in 2020.
    • The loss of $11.18 and $23.44 per stock in Q4 and FY21, respectively.

    Novavax Inc (NVAX) started the vaccine shipments worldwide in FY21. Also, NVAX extended clinical proof for NVX-CoV2373 across a few studies. Moreover, NVAX produced the COVID-19 vaccine, especially for the Omicron variant.

    NVAX News

    Also, On 28 February 2022, the company shared the expanded investigation from its Phase 3 clinical preliminary led in the United Kingdom (UK), showing a significant degree of adequacy for its protein-based COVID-19 vaccine, NVX-CoV2373. Further, the investigation showed immunization viability of 82.5% in assurance against all COVID-19 variants.

    The president of Research and Development, Gregory M. Glenn, commented that vaccine offers the defense against symptomatic and asymptomatic infection of COVID-19. He further added that the vaccine keeps an undeniable degree of sturdy adequacy.

    Fiscal 2022 outlook

    Novavax Inc (NVAX) estimated the revenue for FY22 to be in the range of $4 billion to $5 billion.

  • Novavax, Inc. (NVAX) stock Continues to Gain Premarket. Here’s why?

    Novavax, Inc. (NVAX) stock Continues to Gain Premarket. Here’s why?

    Novavax, Inc. (NVAX) gained a further 9.56% at $238.10 premarket, at the last check on Monday. The stock has been gaining on the news of its Covid-19 vaccine getting Emergency Use Listing from WHO.

    In the previous market session, the stock gained 11.49% at its closing price of $217.32 with 11.12M shares exchanging. NVAX has continued gaining on the news and had increased by $25.00 at the time of writing.

    Currently, the 75.61 million outstanding shares of the company trade at a market capitalization of $16.43 billion.

    Emergency Use Listing for NVX-CoV2373

    On November 17, NVAX and Serum Institute of India Pvt. Ltd. (SII) announced NVAX-CoV2373 has been granted Emergency Use Listing by the WHO. Moreover, the NVAX-CoV2373 is a Covid-19 vaccine for 18 years and older individuals. Furthermore, the EUL was granted to the vaccine manufactured and marketed as COVOVAXTM by SII. COVOVAX is marketed in India along with its licensed areas. In addition, another EUL filing is being reviewed by WHO for the marketing of the vaccine as NuvaxovidTM by Novavax.

    Furthermore, WHO granted the EUL to the vaccine, based on the preclinical, manufacturing, and clinical trial data. Hence, the quality, safety, and efficacy of the vaccine proved to be of the required standards to qualify and attain the EUL.

    According to President and CEO of Novavax, Stanley C. Erck, the EUL authorization is a crucial step for worldwide access to a protein-based Covid-19 vaccine. Previously, COVOVAX was issued EUA in Indonesia and the Philippines. Currently, it is under review by various regulatory authorities throughout the world.

    NVAX’s PREVENT-19 Trial

    On December 15, NVAX published the results of its Phase 3 clinical trial of NVX-CoV2373 in the New England Journal of Medicine. Furthermore, the paper was published under the title ‘Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico’.

    According to the results, the NVX-CoV2373 showed:

    • 100% protection against moderate and severe disease
    • 2% efficacy in case of variants of concern
    • 4% efficacy against Covid-19 of any severity
    • mild-to-moderate and transient solicited adverse events
    • no safety concerns

    NVAX’s Financial Highlights

    On November 04, the company reported its financial results for the third quarter of 2021. Accordingly, NVAX had a net loss of $4.31 per share on revenue of $178.8 million in the third quarter of 2021. This compares to a net loss of $3.21 on revenue of $157.0 million in the year-ago quarter.

  • Novavax, Inc. (NVAX) Stock on the Rise Following Massive Success of PREVENT-19 Study

    Novavax, Inc. (NVAX) Stock on the Rise Following Massive Success of PREVENT-19 Study

    Novavax, Inc. (NVAX) stock prices were up by a marginal 2.31% as of the market closing on June 11th, 2021, bringing the price per share up to USD$209.68 at the end of the trading day. Subsequent pre-market fluctuations have seen the stock surge by 6.57%, bringing it up to USD$223.45.

    Success of PREVENT-19

    The company announced a massively positive outcome for NVX-CoV2373, demonstrating 100% protection against moderate and severe forms of the disease. The treatment also reported an overall efficacy of 90.4% and met its primary endpoint in the PREVENT-19 pivotal Phase 3 trial. The study consisted of a total of 29,960 participants, spanning 119 sites across Mexico and the U.S. The study was designed to evaluate the efficacy, safety, and immunogenicity of the treatment, with an emphasis on representation in the recruitment of communities and demographic groups most impacted by the disease.

    Treatment Poised to Proliferate

    With the world hurtling towards global immunizations as the global coronavirus pandemic continues to take its toll on economies, Novavax is closer to addressing the critical and persistent global public health need. The company continues to work at full capacity to facilitate the completion of regulatory submissions and deliver the vaccine. NVAX has secured a well understood platform with an established track record, through which they will facilitate the provision of the much needed vaccines.

    Next Steps for NVAX

    NVAX anticipates filing for regulatory authorizations in the third quarter of 2021, following the completion of the final phases of process qualification and assay validation needed to meet chemistry, manufacturing, and controls (CMC) requirements. Following the approval, the company will see growth to a manufacturing capacity of 100 million doses per month by the end of the third quarter of 2021. The end of the fourth quarter is expected to mark the ramping up of manufacturing capacity to 150 million doses a month.

    Government Support

    PREVENT-19 has consolidated the tolerability and safety profile of NVX-CoV2373, with data having shown consistent, high levels of efficacy and reaffirm the treatment’s capability to prevent Covid-19 as increasing variants of the virus proliferate international communities. To this end, the treatment has received support from the U.S government, including the DoD, BARDA, parts of the HHS, the NIAID, and more. As per a DoD agreement, BARDA will provide NVAX with USD$1.75 billion.

    Future Outlook for NVAX

    Armed with the fortuitous surge in the value of their equity, NVAX is poise to push for the commercialization and proliferation of its proprietary treatment. The company is keen to continue its trajectory of success and usher in more organic growth over the long-term. Current and potential investors are hopeful that the management will leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • 3 of the Best Biotech Stocks to Buy for 2021

    3 of the Best Biotech Stocks to Buy for 2021

    Due to the spread of the coronavirus pandemic all over the world Biotech stocks have gained great attention in the market. There is great competition between biotech giants, and this makes investors confuse to predict which stock will be more fruitful for them in terms of revenue. But one should not ignore the fact that other diseases and medical challenges still exist even if they are not like that much popular as the COVID-19 is.

    Moderna Inc (NASDAQ: MRNA)

    Moderna, Inc. (MRNA) is a leading mRNA Technology platform that aims on using messenger RNA (mRNA) to produce a new generation of transformative drugs for patients.

    2020 proved to be a good year for Moderna because its share price has reached up to the mark of more than 500%.Covid-19 mRNA-1273 is mainly responsible for this rise as this vaccine has shown very effective results. Further this vaccine has gained the trust of about 30 countries’ regulatory bodies as they have approved it for use.

    According to MichaelYee, a Wall Street analyst, Moderna has already signed $11.7B in contracts in which dose range is from 510M to 525M. The company is looking forward to signing additional contracts for 2021 and 2022 where the capacity will reach up to 1.2B doses.

    Moderna has to compete with its competitors especially Pfizer and JNJ(which is going to share results 3rd trial phase of Covid-19 Vaccine shortly) to maintain its reputation but due to the very high demand for vaccine in the globe, at least five companies can sell at full capacity to fulfill the need of vaccine in the globe. Moderna has also stepped in the 2nd phase study of the age group from 12 to 17 and U.S. Food and Drug may authorize vaccine for teens which could add more value to Moderna’sannual revenue.

    Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

    Vertex Pharmaceutics Inc.(VRTX) is focused on discovering, developing & manufacturing small molecule drugs for the cure of cystic fibrosis, viral infections, bacterial infections, autoimmune diseases, cancer, and neurological disorders.

    The company is playing the lead role in the cure of cystic fibrosis as it is estimated that 50% of patients diagnosed with cystic fibrosis in many countries are using Vertex’s medications. Vertex’s main product is Trikafta which is approved by the FDA at the end of 2019. Trikafta has already generated $3b revenue alone and is expected to generate more in the future as the company is putting serious effort to get the approval of this product for different age groups.

    Novavax, Inc. (NASDAQ: NVAX)

    Novavax, Inc. (NVAX) is a late-stage company that aims in improved global health through the discovery, development, and commercialization of innovative vaccines to prevent infectious disease. The company’s main contributions in preventing diseases include COVID-19, seasonal influenza, RSV, Ebola, Mers, and SARS.

    The company has recently announced that it has contracted with the Government of Canada to supply 76Million doses of NVX-CoV2373, a company’s recombinant protein-based COVID-19 vaccine, to control the pandemic in the region. This contract will help the company to generate a handsome revenue in future.

    Besides the COVID-19 vaccine, the company is putting some serious effort into Nanoflu, a seasonal influenza vaccine for the olders, to influence the global influenza market which will worth more than 6Billion annually by 2026. The 3rd clinical analysis of the Nanoflu showed exceptional results and now the company is expecting to get approval from the U.S food and drug administration soon to commercialize its product and if it happens, it will further boost the company’s reputation and maximize the potential to generate billions of dollars revenue annually.

  • 49 Stocks Making Sharp Moves in Pre Market Session

    49 Stocks Making Sharp Moves in Pre Market Session

    BlackBerry Limited (BB) stock soared 21.29% to $8.49 in the pre-market trading following the announcement of its multi-year, global agreement with Amazon Web Services, Inc. (AWS). The most recent rating by TD Securities, on April 01, 2020, is a Hold.
    Gores Metropoulos Inc. (GMHI), a Shell Companies company, dropped about -3.71% at $16.37 in pre-market trading Wednesday.
    Carnival Corporation & Plc (NYSE: CCL) shares are trading up 2.48% at $20.65 at the time of writing. The firm recently reported Peter C. Anderson as a Section 16 Named Executive Officer. Company’s 52-week ranged between $7.80 to $51.94. Analysts have a consensus price target of $31.
    Guardion Health Sciences Inc. (GHSI) is up more than 2.11% at $0.3 in pre-market hours Wednesday December 02, 2020. The stock had jumped over 11.71% to $0.29 in the last trading session.
    Advaxis Inc. (ADXS) grew over 0.85% at $0.32 in pre-market trading today. The healthcare company recently announced closing of $9.2 million public offering.
    Before the trading started on December 02, 2020, RiceBran Technologies (RIBT) is down -5.56% to reach $0.68. It has been trading in a 52-week range of $0.37 to $2.43.
    Sundial Growers Inc. (SNDL) stock moved up 5.75 percent to $0.69 in the pre-market trading and the company recently announced elimination of senior secured second lien convertible notes.
    Kaixin Auto Holdings (KXIN) is up more than 4.55% at $7.35 in pre-market hours Wednesday December 02, 2020. The stock had jumped over 8.32% to $7.03 in the last trading session.
    Moleculin Biotech Inc. (MBRX) lost over -7.83% at $0.9125 in pre-market trading Wednesday December 02, 2020 after declaring that the US Food and Drug Administration (FDA) has approved its request for a “Rare Pediatric Disease” designation for its drug candidate WP1066.
    Jaguar Health Inc. (JAGX) stock plunged -5.83% to $0.4313 in the pre-market trading. The most recent rating by Rodman & Renshaw, on July 11, 2017, is a Buy.
    Auris Medical Holding Ltd. (EARS) stock plunged -17.97% to $4.29 in the pre-market trading after reporting positive efficacy data from testing AM-301 in vitro. The most recent rating by Euro Pacific Capital, on October 08, 2018, is a Buy.
    Before the trading started on December 02, 2020, Sunworks Inc. (SUNW) is up 9.88% to reach $4.67. It has been trading in a 52-week range of $0.29 to $8.50.
    China Automotive Systems Inc. (NASDAQ: CAAS) shares are trading down -4.95% at $8.25 at the time of writing after the firm declared that its shipped approximately 120,000 units from its portfolio of electric power steering products for use in Chinese electric vehicles during 2020. Company’s 52-week ranged between $1.42 to $10.50.
    Tilray Inc. (NASDAQ: TLRY) shares are trading up 1.61% at $8.2 at the time of writing. Company’s 52-week ranged between $2.43 to $22.95. Analysts have a consensus price target of $4.77.
    Ocugen Inc. (OCGN) lost over -8.87% at $0.3101 in pre-market trading Wednesday December 02, 2020. The company recently reported that leading independent proxy firms ISS and Glass Lewis recommended Ocugen stockholders vote “FOR” reverse stock split and authorized shares amendment proposals.
    AMC Entertainment Holdings Inc. (AMC) is up more than 2.41% at $4.25 in pre-market hours Wednesday December 02, 2020. The stock had dropped over -2.81% to $4.15 in the last trading session.
    Before the trading started on December 02, 2020, JetBlue Airways Corporation (JBLU) is down -4.67% to reach $14.7 following the declaration of its pricing of common stock offering. It has been trading in a 52-week range of $6.61 to $21.65.
    Before the trading started on December 02, 2020, Uxin Limited (UXIN) is down -3.65% to reach $1.32. It has been trading in a 52-week range of $0.72 to $3.10.
    Li Auto Inc. (NASDAQ: LI) shares are trading up 1.78% at $35.48 at the time of writing after announcing that the Company delivered 4,646 Li ONEs in November 2020. Company’s 52-week ranged between $14.31 to $47.70. Analysts have a consensus price target of $45.60.
    Aurora Cannabis Inc. (ACB) stock soared 3.59% to $10.1 in the pre-market trading. The most recent rating by Jefferies, on November 16, 2020, is an Underperform.
    Tantech Holdings Ltd (TANH), a Household & Personal Products company, dropped about -3.24% at $1.79 in pre-market trading Wednesday after reporting the launch by its subsidiary, Shangchi Automobile Co., Ltd., of its newest highly innovative driverless and autonomous street sweeper.
    Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) shares are trading down -5.52% at $1.37 at the time of writing. Company’s 52-week ranged between $0.91 to $9.78. Analysts have a consensus price target of $3.
    iBio Inc. (IBIO) is up more than 19.31% at $1.73 in pre-market hours Wednesday December 02, 2020 after revealing that it has entered into its first Statement of Work (“SoW”) under a Master Services Agreement with ATB Therapeutics to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System. The stock had dropped over -2.68% to $1.45 in the last trading session.
    Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) shares are trading up 2.09% at $23.42 at the time of writing. Company’s 52-week ranged between $7.03 to $59.78. Analysts have a consensus price target of $26.
    Moderna Inc. (MRNA) stock soared 6.09% to $149.6 in the pre-market trading. The biotechnology firm reported recently, that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The most recent rating by Wells Fargo, on November 23, 2020, is an Equal weight.
    Switchback Energy Acquisition Corporation (SBE) is down more than -4.16% at $28.13 in pre-market hours Wednesday December 02, 2020. The stock had dropped over -12.67% to $29.35 in the last trading session.
    Novavax Inc. (NVAX) grew over 4.84% at $129.44 in pre-market trading today after declaring COVID-19 vaccine clinical development progress.
    Before the trading started on December 02, 2020, Eastman Kodak Company (KODK) is up 3.88% to reach $7.5. It has been trading in a 52-week range of $1.50 to $60.00.
    ReneSola Ltd (SOL), a Solar company, dropped about -11.66% at $6.97 in pre-market trading Wednesday after releasing its third quarter 2020 financial results.
    Acasti Pharma Inc. (ACST) stock plunged -9.56% to $0.3301 in the pre-market trading. The most recent rating by Oppenheimer, on September 01, 2020, is a Perform.
    Pfizer Inc. (PFE) stock moved up 3.73 percent to $40.88 in the pre-market trading after the firm and BioNTech SE reporting that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19.
    Gevo Inc. (NASDAQ: GEVO) shares are trading down -3.17% at $1.83 at the time of writing. Company’s 52-week ranged between $0.46 to $2.91.
    Fisker Inc. (FSR) is down more than -3.41% at $17.55 in pre-market hours Wednesday December 02, 2020. The company recently reported that that Henrik Fisker, chairman and chief executive officer of Fisker, will participate in the Credit Suisse Eighth Annual Virtual Industrials Conference. The stock had dropped over -6.24% to $18.17 in the last trading session.
    Nxt-ID Inc. (NXTD) grew over 43.17% at $0.587 in pre-market trading today.
    Before the trading started on December 02, 2020, Bloom Energy Corporation (BE) is down -6.58% to reach $23.0 and the company will host virtual analyst day on December 16, 2020. It has been trading in a 52-week range of $3.00 to $28.24.
    Ocean Power Technologies Inc. (OPTT), a Electrical Equipment & Parts company, dropped about -3.54% at $2.45 in pre-market trading Wednesday.
    Nikola Corporation (NKLA) stock soared 4.38% to $18.13 in the pre-market trading after signing MOU with General Motors. The most recent rating by Loop Capital, on November 20, 2020, is a Buy.
    Vaxart Inc. (VXRT) gained over 3.92% at $7.95 in pre-market trading Wednesday December 02, 2020.
    salesforce.com inc. (CRM) lost over -4.16% at $231.3 in pre-market trading Wednesday December 02, 2020 after introducing service cloud workforce engagement to help contact centers thrive in an all-digital, work-from-anywhere world.
    InVivo Therapeutics Holdings Corp. (NVIV), a Biotechnology company, rose about 2.42% at $0.635 in pre-market trading Wednesday.
    FuelCell Energy Inc. (FCEL) stock plunged -20.11% to $7.23 in the pre-market trading following the publication pricing of its underwritten public offering of 34,518,539 shares of its common stock, at a public offering price of $6.50 per share. The most recent rating by JP Morgan, on November 19, 2020, is a Neutral.
    Pershing Square Tontine Holdings Ltd. (PSTH), a Shell Companies company, rose about 2.34% at $26.25 in pre-market trading Wednesday.
    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading up 4.37% at $29.59 at the time of writing after reporting its new flight window since it paused the spaceflight preparations in response to state guidelines from the New Mexico Department of Health to reduce the spread of COVID-19. Company’s 52-week ranged between $7.14 to $42.49. Analysts have a consensus price target of $19.
    Second Sight Medical Products Inc. (EYES) stock moved down -8.0 percent to $1.38 in the pre-market trading.
    BioNTech SE (BNTX) grew over 7.36% at $122.4 in pre-market trading today after declaring that it will hold a press conference including a video webcast on Wednesday, December 2, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccine candidate BNT162b2.
    Sogou Inc. (SOGO), a Internet Content & Information company, rose about 3.09% at $8.68 in pre-market trading Wednesday.
    Tellurian Inc. (TELL) is down more than -4.29% at $1.56 in pre-market hours Wednesday December 02, 2020 and the firm recently declared the appointment veteran CEO and adds industry experts to board of directors. The stock had jumped over 9.40% to $1.63 in the last trading session.
    Arlo Technologies Inc. (ARLO) lost over -3.48% at $6.66 in pre-market trading Wednesday December 02, 2020.
    Before the trading started on December 02, 2020, ZoomInfo Technologies Inc. (ZI) is down -3.57% to reach $46.22 as the firm announced pricing of secondary offering of shares of class a common stock. It has been trading in a 52-week range of $30.83 to $64.40.

  • Novavax Inc’s (NVAX) shares thundered in the early hours this morning

    Novavax Inc’s (NVAX) stock was up 1.73% to trade at $125.6 in the premarket session today, despite the recent news that the company has again delayed the launch of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine and now plans it to launch next weak instead of November.

    Although difficulties in gearing up the development of the vaccine have delayed the U.S. trial, Novavax has a late-stage study ongoing in the U.K. that concluded enrollment on Monday.

    However, analysts have said that more than one vaccine will be needed to end the pandemic that has killed over 1.4 million people worldwide.

    Duncan added that Novavax expects preliminary results from the U.K. trial in the first quarter of 2021 and may also seek global clearance in the United States and the United Kingdom following the initial data.

    The business plans to use privately manufactured vaccine material for the trial in the United States and Mexico and has collaborated extensively with the United States.

    In the first quarter of next year, the effectiveness evidence from that study will also be available.

  • Surge Continued For Stocks of Vaccine Makers -Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX) Rose On Monday

    Surge Continued For Stocks of Vaccine Makers -Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX) Rose On Monday

    Moderna Inc (MRNA) was up 20.24%on Monday at $152.74. The biotechnology company has therefore applied for marketing authorizations for its coronavirus vaccine in the United States and Europe, which has been shown to be more than 94% successful in advanced clinical trials.

    Pfizer Inc (PFE) gained 2.90 percent to $38.31 and BioNTech SE (BNTX) added 12.96 percent to close at $124.24 on Monday. The drug manufacturing companies were able to receive regulatory approvals in the United Kingdom and the United States for their 95 percent successful vaccine candidate within a few days.

    Novavax Inc (NVAX) saw a rise of 10.99 percent to conclude the trading at $139.50. Stock of soared, while the biotechnology company again postponed the launch in the United States of a Phase III clinical trial of its Covid experimental vaccine, but cited a possible start-up in the coming weeks.

    S&P Global Inc (SPGI) was up 2.99 percent to $351.78. As expected, it announced IHS Markit’s acquisition of $44 billion in shares, the biggest merger and value acquisition since the beginning of the year. The total capitalization of IHS Markit is $37 billion.

    Airbnb is looking for a $30 billion to $33 billion valuation for its Wall Street IPO. Food distribution player, DoorDash, with its more than tripled sales in nine months and first quarterly profit, is also greedy for its IPO with a cap from $25 billion to $28 billion. Both companies are planning to join the Wall Street in mid-December.

    Netflix Inc (NFLX) slipped -0.13 percent to $490.70 in the last session. The video streaming service is expected to begin disclosing revenue of more than GBP 1 billion from British subscribers to tax authorities in the UK, according to the Guardian. The Guardian claims that Netflix’s decision could place pressure on other U.S. tech giants such as Google or Amazon, who are currently preventing such reporting by optimizing their taxation.